• Hazhee Rasoul, Saad Fyyaz, Daniela Noakes, Carl Shakespeare, Sarojini David, Zeeshan M Khawaja, Nikolaos Papamichail, and Khaled Alfakih.
• Lewisham and Greenwich NHS Trust, London, UK.
• Clin Med (Lond). 2021 Mar 1; 21 (2): 909590-95.

BackgroundThe National Institute for Health and Care Excellence (NICE) 2016 guidelines (CG95) recommend patients with new stable chest pain be investigated with computed tomography coronary angiography (CTCA). An updated guideline (MTG32) recommended using CT fractional flow reserve (CTFFR) as a gatekeeper to invasive coronary angiography (ICA) for patients with coronary stenosis on CTCA. Subsequently, NHS England negotiated a UK-wide contract with HeartFlow, the provider of CTFFR. We describe our experience with CTFFR and consider the impact of the recent ISCHEMIA trial on these guidelines.MethodsWe prospectively collected ICA and revascularisation data on all patients undergoing CTFFR from January 2019 to March 2020.ResultsOne-hundred and twenty-five of 140 patients completed CTFFR analysis. Eighty-one patients had CTCA stenosis >50%. Thirty-six had positive CTFFR; 29 underwent ICA with 22 (75.9%) revascularised. Forty-five had negative CTFFR; 14 underwent ICA and four (28.6%) were revascularised. The average cost of investigation per patient (PP) was £971.95. Had these patients undergone ICA directly with no functional test after CTCA, the average cost would be £932.51 PP.ConclusionOur revascularisation rates suggest that CTFFR can potentially be a gatekeeper to ICA but does not necessarily yield cost savings.© Royal College of Physicians 2021. All rights reserved.

17 keywords...

hide…